Med-tech MNCs see healthy market space

A1 The CIIE is an important opportunity for many multinational companies, including Sanofi, to share the dividends of China's opening-up and development. It plays an important role in promoting cooperation, increasing confidence, and building an ecosystem for the innovation and prosperity of the healthcare industry.

At the fifth CIIE, Sanofi exhibited 23 strategic and star innovative products covering complex healthcare issues such as rare immune and inflammatory diseases, chronic diseases, vaccines and consumer healthcare products — including five new products making their debut in China. We are looking forward to contributing to the Healthy China 2030 plan by leveraging our global R&D strengths and local insights through this important platform.

A2 Against the backdrop of the continued COVID-19 situation, the CIIE has sent to the world a message of openness, tolerance, inclusivity and mutual prosperity, while also showing its resilience amid multiple disruptions and challenges. The expo's "spillover effect" also bolsters the long-term confidence of multinational enterprises to continue their development in China. Sanofi looks forward to leveraging the CIIE platform and its spillover effect to bring more, faster and better innovative medical solutions to Chinese patients.

A3 China is not only the world's second-largest economy, but also a major contributor to global economic growth. The high level of opening-up it adheres to has given a strong impetus to the development of the world economy.

China is always at the center of our global strategy. Looking ahead, we are equally upbeat about China and will seize innovative insights for the healthcare sector's development while enthusiastically exploring new treatments for patients.

A4 China's economic pattern has evolved from one featuring "quantity-driven growth" to "high-quality development". Innovation holds the key to this critical transformation and Sanofi shares that very sentiment to fuel our own business.

For Sanofi, we will continue to innovate to improve people's lives by consistently accelerating the introduction of innovative medicines and vaccines, enhancing accessibility to innovative medicines and focusing on digital innovation to enhance efficiency.

A5 In recent years, we have felt China's determination and confidence in encouraging innovation more deeply, which is creating an internationally first-class business environment. By promoting a new model of high-level opening-up, China is actively supporting the foreign investment environment, providing more opportunities for foreign pharmaceutical companies to better develop in China. We are honored to be both a witness and a beneficiary of China's reform and opening-up policy.